表紙
市場調査レポート

T細胞白血病:パイプライン製品の分析

T-Cell Leukemia - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 229778
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
T細胞白血病:パイプライン製品の分析 T-Cell Leukemia - Pipeline Review, H2 2015
出版日: 2015年09月16日 ページ情報: 英文 91 Pages
概要

T細胞の癌はT細胞白血病として知られ、制御できない白血球の成長が特徴で、正常細胞の欠乏をもたらします。そのため、免疫システムに影響し、感染症に非常にかかりやすくなります。T細胞白血病の素因は放射線と化学薬品の被爆によるものが素因です。症状は反復性感染、痛み、出血、および疲労という形で現れますが、化学療法、幹細胞移植および薬物治療によって症状をコントロールすることもできます。

当レポートでは、T細胞白血病の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

T細胞白血病の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

T細胞白血病:企業で開発中の治療薬

T細胞白血病:大学/機関で研究中の治療薬

T細胞白血病:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

T細胞白血病:企業で開発中の製品

T細胞白血病:大学/機関で研究中の製品

T細胞白血病の治療薬開発に従事している企業

  • Applied Immune Technologies Ltd
  • アステラス製薬
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chipscreen Biosciences Ltd
  • iDD biotech SAS
  • 協和発酵キリン
  • MediGene AG
  • Sanofi
  • Stemline Therapeutics, Inc.
  • Theravectys SA

T細胞白血病:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • AGS-67E
  • alemtuzumab
  • HLA-A2を阻害する抗体
  • BMS-906024
  • CD38を標的とする細胞治療
  • CS-055
  • IDD-003
  • INA-01
  • L-1AD3
  • lenalidomide
  • MMIG-202
  • mogamulizumab
  • モノクローナル抗体
  • 糖タンパク質を標的とする腫瘍溶解性ウイルス
  • SL-101
  • THV-02

T細胞白血病:最近のパイプライン動向

T細胞白血病:休止中のプロジェクト

T細胞白血病:開発が中止された製品

T細胞白血病:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7107IDB

Summary

Global Markets Direct's, 'T-Cell Leukemia - Pipeline Review, H2 2015', provides an overview of the T-Cell Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for T-Cell Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding T-Cell Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • T-Cell Leukemia Overview
  • Therapeutics Development
    • Pipeline Products for T-Cell Leukemia - Overview
    • Pipeline Products for T-Cell Leukemia - Comparative Analysis
  • T-Cell Leukemia - Therapeutics under Development by Companies
  • T-Cell Leukemia - Therapeutics under Investigation by Universities/Institutes
  • T-Cell Leukemia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • T-Cell Leukemia - Products under Development by Companies
  • T-Cell Leukemia - Products under Investigation by Universities/Institutes
  • T-Cell Leukemia - Companies Involved in Therapeutics Development
    • Applied Immune Technologies Ltd
    • Astellas Pharma Inc.
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Chipscreen Biosciences Ltd
    • iDD biotech SAS
    • Kyowa Hakko Kirin Co., Ltd.
    • MediGene AG
    • Sanofi
    • Stemline Therapeutics, Inc.
    • Theravectys SA
  • T-Cell Leukemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGS-67E - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alemtuzumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibody to Inhibit HLA-A2 for Neurology, Infectious Diseases and T-Cell Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-906024 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target CD38 for cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CS-055 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IDD-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INA-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • L-1AD3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MMIG-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mogamulizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Antagonize TCR for Leukemia and Autoimmune Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Target CCR9 for T Lymphoblastic Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oncolytic Virus to Target Glycoprotein gp160 for T-cell Leukemia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • THV-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • T-Cell Leukemia - Recent Pipeline Updates
  • T-Cell Leukemia - Dormant Projects
  • T-Cell Leukemia - Discontinued Products
  • T-Cell Leukemia - Product Development Milestones
    • Featured News & Press Releases
      • Mar 23, 2015: THERAVECTYS Granted Authorization by the French National Agency for Medicines to Produce Lentiviral Vectors for Clinical Use and CAR-T Cell Therapies under GMP Standards
      • Feb 04, 2015: THERAVECTYS Obtains Orphan Drug Designation from the European Medicines Agency for Its Lentiviral Vector-Based Therapeutic Vaccine against Adult T-Cell Leukemia and Lymphoma
      • Dec 18, 2014: Approval for Additional Indication for Chemotherapy-Native CCR4-positive ATL of Mogamulizumab
      • Sep 29, 2014: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study
      • Aug 23, 2012: Kyowa Hakko Kirin Initiates Pivotal Phase II Trial Of Mogamulizumab In Patients With Adult T-cell Leukemia-Lymphoma In US And Europe
      • Jul 19, 2012: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab
      • May 29, 2012: Kyowa Hakko Kirin Launches POTELIGEO Injection In Japan
      • Jan 25, 2012: Study Shows Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity
      • Dec 07, 2010: Kyowa Hakko Kirin Announces Results From Japan Phase II Clinical Trial Of KW-0761 In Adult T-Cell Leukemia-Lymphoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for T-Cell Leukemia, H2 2015
  • Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • T-Cell Leukemia - Pipeline by Applied Immune Technologies Ltd, H2 2015
  • T-Cell Leukemia - Pipeline by Astellas Pharma Inc., H2 2015
  • T-Cell Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • T-Cell Leukemia - Pipeline by Celgene Corporation, H2 2015
  • T-Cell Leukemia - Pipeline by Chipscreen Biosciences Ltd, H2 2015
  • T-Cell Leukemia - Pipeline by iDD biotech SAS, H2 2015
  • T-Cell Leukemia - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
  • T-Cell Leukemia - Pipeline by MediGene AG, H2 2015
  • T-Cell Leukemia - Pipeline by Sanofi, H2 2015
  • T-Cell Leukemia - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • T-Cell Leukemia - Pipeline by Theravectys SA, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • T-Cell Leukemia Therapeutics - Recent Pipeline Updates, H2 2015
  • T-Cell Leukemia - Dormant Projects, H2 2015
  • T-Cell Leukemia - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for T-Cell Leukemia, H2 2015
  • Number of Products under Development for T-Cell Leukemia - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top